Seek Returns

RGEN vs. TEM: Repligen vs. Tempus AI Stock Comparison

How do Repligen (RGEN) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Repligen (RGEN) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Repligen (RGEN) carries decades of public-market history since April 29, 1986, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the RGEN side.

Company profile comparison for Repligen (RGEN) and Tempus AI (TEM)
Profile ItemRGENTEM
NameRepligen CorporationTempus AI Inc Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization11.09 billion USD13.87 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateApril 29, 1986June 14, 2024
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

RGEN
TEM
GSPC
Loading price history…
Repligen (RGEN) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Repligen (RGEN) and Tempus AI (TEM). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Repligen (RGEN) and Tempus AI (TEM). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
Total Return (1Y)23.28%16.25%
Total Return (3Y, Annualized)6.20%--
Total Return (5Y, Annualized)-8.41%--

Risk Profile

Drawdown History

RGEN
TEM
GSPC
Loading price history…
Repligen (RGEN) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Repligen (RGEN) and Tempus AI (TEM). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Repligen (RGEN) is closer to market-like at 1.11 — a noticeable difference in market-sensitivity profile.

Risk profile metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
Volatility (1Y, Annualized)46.73%76.08%
Beta (5Y)1.113.34
Max Drawdown (5Y)-64.67%-59.76%
Avg. Volume (3M)1.18M7.20M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RGEN and TEM are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
Sharpe Ratio (1Y)0.410.16
Sortino Ratio (1Y)0.600.26

Profitability

ROE (TTM)

Both Repligen (RGEN) at -0.57% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-37.55%

Max
109.18%
Q3
6.23%
Median
-26.66%
TEM
-37.55%
Q1
-64.05%
Min
-167.77%
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Repligen (RGEN) at -1.47% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.54%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
TEM
-12.54%
Min
-17.05%
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Repligen (RGEN) reports 6.19%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-13.82%

Max
83.12%
Q3
14.77%
Median
0.00%
TEM
-13.82%
Q1
-78.82%
Min
-207.40%
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
ROE (TTM)-0.57%-37.55%
ROA (TTM)1.40%-7.36%
Net Margin (TTM)-1.47%-12.54%
Operating Margin (TTM)6.19%-13.82%
Gross Margin (TTM)53.77%64.46%

Growth

Revenue Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Repligen (RGEN) at 16.36% is closer to the peer norm — faster top-line expansion for TEM.

Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Repligen (RGEN) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
Revenue Growth (YoY)16.36%83.41%
Revenue Growth (3Y CAGR)-2.70%58.29%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)-35.73%--

Financial Strength

Current Ratio (MRQ)

Both Repligen (RGEN) at 9.88 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.61

Max
25.13
Q3
12.13
Median
5.52
TEM
2.61
Q1
2.47
Min
0.10
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Repligen (RGEN) at 0.33 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

TEM
2.86
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
Current Ratio (MRQ)9.882.61
Debt / Equity (MRQ)0.332.86
Net Debt / EBITDA-1.19--

Dividends

Dividend Yield (TTM)

Neither Repligen (RGEN) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Repligen (RGEN) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Repligen (RGEN) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
TEM
--
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

On P/S ratio, both Repligen (RGEN) at 13.77 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.19

Max
58.18
Q3
25.77
TEM
9.19
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.66

TEM
27.66
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Repligen (RGEN) vs. Tempus AI (TEM): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Repligen (RGEN) and Tempus AI (TEM)
MetricRGENTEM
P/E Ratio (TTM)----
P/S Ratio (TTM)13.779.19
P/B Ratio (MRQ)4.7027.66
Free Cash Flow Yield (TTM)1.01%0.30%